Patent expirations won't hold back success of some drug firms

11/18/2003 | Bloomberg Businessweek

Although many drug firms are facing patent expirations next year, investors are bullish on several companies. For example, Pfizer is favored among investors based on anticipated 2004 sales of its recently approved drug for congestive heart failure. Abbott recently launched Humira, a rheumatoid arthritis drug that could be a hit, while Wyeth's lack of patent expirations could outweigh its weak pipeline.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health